STARTUP PROFILE

Epia Neuro

COUNTRY
USA
FOUNDED
2021
CATEGORY
Brain-Computer Interface
Developing minimally invasive brain-computer interfaces that decode motor intent and pair neural sensing with stimulation to restore function after stroke.
Visit website →
Market Notes · Biweekly

Track this company

Funding, launches and regulatory moves across the neurotech startup map.

Subscribed. Check your inbox to confirm.

Epia Neuro

news and updates

  • 2 Apr 2026: Epia Neuro emerged from stealth in San Francisco. It is led by CEO Michel Maharbiz, founder of iota Biosciences and co-inventor of neural dust. Its 64-channel implant sits above the dura over the motor cortex and takes under an hour to implant. It is charged through a headset and drives a grip-assist prosthetic for chronic stroke survivors with upper-limb impairment. Epia has not disclosed its funding or investors. Read our coverage.
  • Planned: First-in-human implantation at Lenox Hill Hospital in New York in 2026, with an FDA submission targeted for February 2027.
•
Neurofounders Insights
$   Funding   -
Unknown
MODALITY
ECoG
FORM FACTOR
Implant
INTERFACE DEPTH
Implantable
INDICATION
Stroke
TARGET USER
Clinicians
REGULATORY STAGE
Preclinical
Epia neuro has minimal public information available, making detailed competitive analysis difficult. Based on the domain name and URL, the company appears to operate in the epilepsy diagnostics or monitoring space, placing it adjacent to Ceribell and Epitel, though the specific modality, form factor, and regulatory stage remain undisclosed.
•
Mentioned in Market Notes
MOST RECENT COVERAGE
No items found.
Articles featuring
Epia Neuro